Xenon Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Xenon Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- Canada
- Ticker symbol
- XENE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001582313
Board of directors
-
Dawn Svoronos · DirectorSince 2023
-
Elizabeth A. Garofalo · DirectorSince 2023
-
Gary Patou · DirectorSince 2023
-
Gillian Cannon · DirectorSince 2023
-
Ian Mortimer · Director · PRESIDENT & CEOSince 2023
-
Justin D. Gover · DirectorSince 2023
-
Mohammad Azab · DirectorSince 2023
-
Patrick Machado · DirectorSince 2023
-
Simon N. Pimstone · DirectorSince 2023
-
Steven Gannon · DirectorSince 2023
Chief executives
Ian Mortimer
· PRESIDENT & CEO
Dates unknown
Board connections
4 of this board's directors also sit on 5 other boards.
- via Elizabeth A. Garofalo
- via Elizabeth A. Garofalo
- via Patrick Machado
- via Gillian Cannon
- via Mohammad Azab
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 8, 2024 | Elizabeth A. Garofalo Director | Option exercise | +3,500 | $18.56 | $64,960 |
| Mar 8, 2024 | Elizabeth A. Garofalo Director | Shares withheld for tax | −1,408 | $46.16 | $64,993 |
| Mar 8, 2024 | Elizabeth A. Garofalo Director | Open-market sale | −2,092 | $45.69 | $95,583 |
| Mar 7, 2024 | ROBIN SHERRINGTON Officer (EVP, Strategy & Innovation) | Option exercise | +1,234 | $9.85 | $12,155 |
| Mar 7, 2024 | Steven Gannon Director | Open-market sale | −1,000 | $46.45 | $46,450 |
| Mar 7, 2024 | ROBIN SHERRINGTON Officer (EVP, Strategy & Innovation) | Shares withheld for tax | −215 | $45.96 | $9,881 |
| Mar 7, 2024 | Steven Gannon Director | Open-market sale | −5,000 | $46.25 | $231,250 |
| Mar 7, 2024 | ROBIN SHERRINGTON Officer (EVP, Strategy & Innovation) | Option exercise | +7,407 | $9.85 | $72,959 |
| Mar 7, 2024 | Steven Gannon Director | Open-market sale | −5,000 | $46.30 | $231,500 |
| Mar 7, 2024 | ROBIN SHERRINGTON Officer (EVP, Strategy & Innovation) | Shares withheld for tax | −1,289 | $45.96 | $59,242 |
| Mar 7, 2024 | Steven Gannon Director | Open-market sale | −2,000 | $46.20 | $92,400 |
| Mar 7, 2024 | ROBIN SHERRINGTON Officer (EVP, Strategy & Innovation) | Open-market sale | −1,019 | $46.15 | $47,027 |
| Mar 7, 2024 | ROBIN SHERRINGTON Officer (EVP, Strategy & Innovation) | Open-market sale | −6,118 | $46.30 | $283,263 |
| Dec 19, 2023 | Mohammad Azab Director | Option exercise | +823 | $9.85 | $8,107 |
| Dec 19, 2023 | Mohammad Azab Director | Option exercise | +3,497 | $9.85 | $34,445 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.